ReviewGalen medical journal2024
Investigating The Antifungal Activity of Atorvastatin Compared with Nystatin on Oral Candidiasis before and during Head and Neck Radiotherapy.
Review in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy plays an imperative role in the control of head and neck malignancies; however, it can damage oral tissues and salivary glands. These damages can alter oral Candida species and lead to the expansion of oral candidiasis resistant to common antifungal mediators, including nystatin. Atorvastatin, a serum cholesterol-lowering drug, has potential antifungal activities by inhibiting the synthesis of ergosterol in the fungal wall and disrupting mitochondrial function. This study aimed to determine and equivalence the antifungal activities of nystatin and atorvastatin on Candida species isolated from the mouths of patients undergoing head and neck radiotherapy before and during radiotherapy. MATERIALS AND
methodsThis was an in vitro laboratory research conducted on samples isolated from patients experiencing head and neck radiotherapy, before and during radiotherapy. After determining the Candida species using the PCR-RFLP method, the antifungal activity of both nystatin and atorvastatin was evaluated by microdilution method according to CLSI standards, and the minimum inhibitory concentration (MIC) and minimum lethal concentration (MFC) of each drug were measured.
resultsAccording to our findings, atorvastatin had less activity in inhibiting and killing different Candida species compared to nystatin before and during radiotherapy. Before radiotherapy, the MIC and MFC indices for nystatin against Candida albicans (P0.001), tropical (P0.001) and glabrata (P0.001) were significantly lower than these three indices (P-value0.001) for atorvastatin. The results of these indices in the second week of radiotherapy were similar to the results before radiotherapy. The MIC and MFC results for Candida albicans and tropicalis were obtained with a P-value0.001 and for glabrata with a P-value = 0.002.
conclusionThe discoveries of this study indicate that atorvastatin exhibits lower antifungal activity compared to nystatin in treating oral candidiasis among patients receiving head and neck radiotherapy, both before and during the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.